Alessia Pepe

List of Publications by Year
in descending order

93 papers	2,941 citations	186265 28 h-index	189892 50 g-index
95 all docs	95 docs citations	95 times ranked	2227 citing authors

#	Article	IF	Citations
1	Multislice multiecho T2* cardiovascular magnetic resonance for detection of the heterogeneous distribution of myocardial iron overload. Journal of Magnetic Resonance Imaging, 2006, 23, 662-668.	3.4	173
2	Cardiac and hepatic iron and ejection fraction in thalassemia major: Multicentre prospective comparison of combined Deferiprone and Deferoxamine therapy against Deferiprone or Deferoxamine Monotherapy. Journal of Cardiovascular Magnetic Resonance, 2013, 15, 1.	3.3	167
3	Deferasirox, deferiprone and desferrioxamine treatment in thalassemia major patients: cardiac iron and function comparison determined by quantitative magnetic resonance imaging. Haematologica, 2011, 96, 41-47.	3.5	129
4	StandardizedT2* map of normal human heartin vivo to correctT2* segmental artefacts. NMR in Biomedicine, 2007, 20, 578-590.	2.8	119
5	Improved T2* assessment in liver iron overload by magnetic resonance imaging. Magnetic Resonance Imaging, 2009, 27, 188-197.	1.8	119
6	Evaluation of the efficacy of oral deferiprone in beta-thalassemia major by multislice multiecho T2*. European Journal of Haematology, 2006, 76, 183-192.	2.2	115
7	Multicenter validation of the magnetic resonance t2* technique for segmental and global quantification of myocardial iron. Journal of Magnetic Resonance Imaging, 2009, 30, 62-68.	3.4	115
8	Cardiac iron and cardiac disease in males and females with transfusion-dependent thalassemia major: a T2* magnetic resonance imaging study. Haematologica, 2011, 96, 515-520.	3.5	107
9	Multimodality Imaging in Restrictive Cardiomyopathies: An EACVI expert consensus document In collaboration with the â€œWorking Group on myocardial and pericardial diseasesâ€•of the European Society of Cardiology Endorsed by The Indian Academy of Echocardiography. European Heart Journal Cardiovascular Imaging, 2017, 18, 1090-1121.	1.2	91
10	Guideline recommendations for heart complications in thalassemia major. Journal of Cardiovascular Medicine, 2008, 9, 515-525.	1.5	84
11	Reference values of cardiac volumes, dimensions, and new functional parameters by MR: A multicenter, multivendor study. Journal of Magnetic Resonance Imaging, 2017, 45, 1055-1067.	3.4	82
12	Prediction of cardiac complications for thalassemia major in the widespread cardiac magnetic resonance era: a prospective multicentre study by a multi-parametric approach. European Heart Journal Cardiovascular Imaging, 2018, 19, 299-309.	1.2	74
13	Single region of interest versus multislice T2* MRI approach for the quantification of hepatic iron overload. Journal of Magnetic Resonance Imaging, 2011, 33, 348-355.	3.4	71
14	The use of appropriate calibration curves corrects for systematic differences in liver <scp>R</scp>2* values measured using different software packages. British Journal of Haematology, 2013, 161, 888-891.	2.5	67
15	Preferential patterns of myocardial iron overload by multislice multiecho <i>T</i>*₂ CMR in thalassemia major patients. Magnetic Resonance in Medicine, 2010, 64, 211-219.	3.0	64
16	Multiparametric Cardiac Magnetic Resonance Survey in Children With Thalassemia Major. Circulation: Cardiovascular Imaging, 2015, 8, e003230.	2.6	62
17	Cardiac complications and diabetes in thalassaemia major: a large historical multicentre study. British Journal of Haematology, 2013, 163, 520-527.	2.5	48
18	Increased survival and reversion of iron-induced cardiac disease in patients with thalassemia major receiving intensive combined chelation therapy as compared to desferoxamine alone. Blood Cells, Molecules, and Diseases, 2010, 45, 136-139.	1.4	45

#	Article	IF	Citations
19	Diabetes and Glucose Metabolism in Thalassemia Major: An Update. Expert Review of Hematology, 2016, 9, 401-408.	2.2	45
20	Myocardial iron overload in thalassaemia major. How early to check?. British Journal of Haematology, 2014, 164, 579-585.	2.5	43
21	Multislice multiecho T2* cardiac magnetic resonance for the detection of heterogeneous myocardial iron distribution in thalassaemia patients. NMR in Biomedicine, 2009, 22, 707-715.	2.8	42
22	Cardiac magnetic resonance predicts ventricular arrhythmias in scleroderma: the Scleroderma Arrhythmia Clinical Utility Study (SAnCtUS). Rheumatology, 2020, 59, 1938-1948.	1.9	42
23	Different patterns of myocardial iron distribution by whole-heart T2* magnetic resonance as risk markers for heart complications in thalassemia major. International Journal of Cardiology, 2014, 177, 1012-1019.	1.7	40
24	Pattern of complications and burden of disease in patients affected by beta thalassemia major. Current Medical Research and Opinion, 2017, 33, 1525-1533.	1.9	40
25	The Close Link of Pancreatic Iron With Glucose Metabolism and With Cardiac Complications in Thalassemia Major: A Large, Multicenter Observational Study. Diabetes Care, 2020, 43, 2830-2839.	8.6	39
26	Regional and global pancreatic <i>T</i>*₂ MRI for iron overload assessment in a large cohort of healthy subjects: Normal values and correlation with age and gender. Magnetic Resonance in Medicine, 2011, 65, 764-769.	3.0	38
27	MRI multicentre prospective survey in thalassaemia major patients treated with deferasirox <i>versus</i> deferiprone and desferrioxamine. British Journal of Haematology, 2018, 183, 783-795.	2.5	33
28	Multicenter validation of the magnetic resonance T2* technique for quantification of pancreatic iron. European Radiology, 2019, 29, 2246-2252.	4.5	32
29	Improvement of heart iron with preserved patterns of iron store by CMR-guided chelation therapy. European Heart Journal Cardiovascular Imaging, 2015, 16, 325-334.	1.2	31
30	Safety of cardiovascular magnetic resonance gadolinium chelates contrast agents in patients with hemoglobinopathies. Haematologica, 2009, 94, 1625-1627.	3.5	29
31	Influence of myocardial fibrosis and blood oxygenation on heart T2* values in thalassemia patients. Journal of Magnetic Resonance Imaging, 2009, 29, 832-837.	3.4	28
32	Pancreatic iron overload by <scp>T</scp>2* <scp>MRI</scp> in a large cohort of well treated thalassemia major patients: Can it tell us heart iron distribution and function?. American Journal of Hematology, 2015, 90, E189-90.	4.1	26
33	Accurate estimate of pancreatic T2* values: how to deal with fat infiltration. Abdominal Imaging, 2015, 40, 3129-3136.	2.0	26
34	Survival and causes of death in 2,033 patients with non-transfusion-dependent Î2-thalassemia. Haematologica, 2021, 106, 2489-2492.	3.5	25
35	National networking in rare diseases and reduction of cardiac burden in thalassemia major. European Heart Journal, 2022, 43, 2482-2492.	2.2	25
36	Myocardial fibrosis by late gadolinium enhancement cardiac magnetic resonance and hepatitis C virus infection in thalassemia major patients. Journal of Cardiovascular Medicine, 2015, 16, 689.	1.5	23

#	Article	IF	Citations
37	Extramedullary hematopoiesis is associated with lower cardiac iron loading in chronically transfused thalassemia patients. American Journal of Hematology, 2015, 90, 1008-1012.	4.1	22
38	Clinical recommendations of cardiac magnetic resonance, Part II. Journal of Cardiovascular Medicine, 2017, 18, 209-222.	1.5	22
39	Detection of myocardial iron overload by two-dimensional speckle tracking in patients with beta-thalassaemia major: a combined echocardiographic and T2* segmental CMR study. International Journal of Cardiovascular Imaging, 2018, 34, 263-271.	1.5	22
40	Biventricular Reference Values by Body Surface Area, Age, and Gender in a Large Cohort of Wellâ€Treated Thalassemia Major Patients Without Heart Damage Using a Multiparametric <scp>CMR</scp> Approach. Journal of Magnetic Resonance Imaging, 2021, 53, 61-70.	3.4	22
41	Myocardial iron overload by cardiovascular magnetic resonance native segmental T1 mapping: a sensitive approach that correlates with cardiac complications. Journal of Cardiovascular Magnetic Resonance, 2021, 23, 70.	3.3	22
42	Diagnostic Accuracy of CT Texture Analysis in Adrenal Masses: A Systematic Review. International Journal of Molecular Sciences, 2022, 23, 637.	4.1	22
43	Cardiovascular magnetic resonance in autoimmune rheumatic diseases: a clinical consensus document by the European Association of Cardiovascular Imaging. European Heart Journal Cardiovascular Imaging, 2022, 23, e308-e322.	1.2	21
44	Standardized T2* Map of a Normal Human Heart to Correct T2* Segmental Artefacts; Myocardial Iron Overload and Fibrosis in Thalassemia IntermediaVersusThalassemia Major Patients and Electrocardiogram Changes in Thalassemia Major Patients. Hemoglobin, 2008, 32, 97-107.	0.8	20
45	Comparison of biventricular dimensions and function between pediatric sickleâ€cell disease and thalassemia major patients without cardiac iron. American Journal of Hematology, 2013, 88, 213-218.	4.1	20
46	Gender differences in the development of cardiac complications: a multicentre study in a large cohort of thalassaemia major patients to optimize the timing of cardiac followâ€up. British Journal of Haematology, 2018, 180, 879-888.	2.5	20
47	Fast generation of T2âŽ maps in the entire range of clinical interest: Application to thalassemia major patients. Computers in Biology and Medicine, 2015, 56, 200-210.	7.0	19
48	Cardiovascular magnetic resonance in women with cardiovascular disease: position statement from the Society for Cardiovascular Magnetic ResonanceÂ(SCMR). Journal of Cardiovascular Magnetic Resonance, 2021, 23, 52.	3.3	19
49	Myocardial <scp>T1</scp> Values at 1.5â€‰T: Normal Values for General Electric Scanners and Sexâ€Related Differences. Journal of Magnetic Resonance Imaging, 2021, 54, 1486-1500.	3.4	18
50	Cardiovascular imaging in the diagnosis and monitoring of cardiotoxicity. Journal of Cardiovascular Medicine, 2016, 17, e45-e54.	1.5	17
51	Cost-Utility Analysis of Three Iron Chelators Used in Monotherapy for the Treatment of Chronic Iron Overload in Î²-Thalassaemia Major Patients: An Italian Perspective. Clinical Drug Investigation, 2017, 37, 453-464.	2.2	17
52	Nontraditional Cardiovascular Biomarkers and Risk Factors: Rationale and Future Perspectives. Biomolecules, 2018, 8, 40.	4.0	16
53	Quantitative T2* magnetic resonance imaging for renal iron overload assessment: normal values by age and sex. Abdominal Imaging, 2015, 40, 1700-1704.	2.0	14
54	The impact of liver steatosis on the ability of serum ferritin levels to be predictive of liver iron concentration in nonâ€transfusionâ€dependent thalassaemia patients. British Journal of Haematology, 2018, 180, 721-726.	2.5	14

#	Article	IF	Citations
55	Soluble form of transferrin receptor as a biomarker of overall morbidity in patients with non-transfusion-dependent thalassaemia: a cross-sectional study. Blood Transfusion, 2016, 14, 538-540.	0.4	14
56	The Italian multiregional thalassemia registry: Centers characteristics, services, and patientsâ€™ population. Hematology, 2016, 21, 415-424.	1.5	12
57	CMR for myocardial iron overload quantification: calibration curve from the MIOT Network. European Radiology, 2020, 30, 3217-3225.	4.5	12
58	Extramedullary haematopoiesis correlates with genotype and absence of cardiac iron overload in polytransfused adults with thalassaemia. Blood Transfusion, 2014, 12 Suppl 1, s124-30.	0.4	12
59	Soluble form of transferrin receptor-1 level is associated with the age at first diagnosis and the risk of therapeutic intervention and iron overloading in patients with non-transfusion-dependent thalassemia. Annals of Hematology, 2017, 96, 1541-1546.	1.8	11
60	Left Ventricular Volumes, Mass and Function normalized to the body surface area, age and gender from CMR in a large cohort of well-treated Thalassemia Major patients without myocardial iron overload. Journal of Cardiovascular Magnetic Resonance, 2011, 13, .	3.3	10
61	Longitudinal followâ€up of patients with thalassaemia intermedia who started transfusion therapy in adulthood: a cohort study. British Journal of Haematology, 2020, 191, 107-114.	2.5	10
62	The Link of Pancreatic Iron with Glucose Metabolism and Cardiac Iron in Thalassemia Intermedia: A Large, Multicenter Observational Study. Journal of Clinical Medicine, 2021, 10, 5561.	2.4	10
63	Left ventricle remodeling in patients with Î²-thalassemia major. An emerging differential diagnosis with left ventricle noncompaction disease. Clinical Imaging, 2017, 45, 58-64.	1.5	9
64	Estimation of pancreatic R2* for iron overload assessment in the presence of fat: a comparison of different approaches. Magnetic Resonance Materials in Physics, Biology, and Medicine, 2018, 31, 757-769.	2.0	9
65	Cardiac involvement by CMR in different genotypic groups of thalassemia major patients. Blood Cells, Molecules, and Diseases, 2019, 77, 1-7.	1.4	9
66	Myocardial T2 values at 1.5 T by a segmental approach with healthy aging and gender. European Radiology, 2022, 32, 2962-2975.	4.5	9
67	A critical review of non invasive procedures for the evaluation of body iron burden in thalassemia major patients. Pediatric Endocrinology Reviews, 2008, 6 Suppl 1, 193-203.	1.2	9
68	Cardiac R2* values are independent of the image analysis approach employed. Magnetic Resonance in Medicine, 2014, 72, 485-491.	3.0	8
69	Non-compact myocardium assessment by cardiac magnetic resonance: dependence on image analysis method. International Journal of Cardiovascular Imaging, 2018, 34, 1227-1238.	1.5	8
70	Expert Opinion on Managing Chronic HCV in Patients with Cardiovascular Disease. Antiviral Therapy, 2018, 23, 35-46.	1.0	8
71	A complication risk score to evaluate clinical severity of thalassaemia syndromes. British Journal of Haematology, 2021, 192, 626-633.	2.5	7
72	The prognostic role of CMR using global planimetric criteria in patients with excessive left ventricular trabeculation. European Radiology, 2021, 31, 7553-7565.	4.5	7

#	Article	IF	Citations
73	Serum Organ-Specific Anti-Heart and Anti-Intercalated Disk Autoantibodies as New Autoimmune Markers of Cardiac Involvement in Systemic Sclerosis: Frequency, Clinical and Prognostic Correlates. Diagnostics, 2021, 11, 2165.	2.6	7
74	Evaluation of myocardial iron overload using cardiovascular magnetic resonance imaging. Hellenic Journal of Cardiology, 2011, 52, 385-90.	1.0	7
75	Deep Learning Staging of Liver Iron Content From Multiecho MR Images. Journal of Magnetic Resonance Imaging, 2023, 57, 472-484.	3.4	6
76	The effect of desferrioxamine chelation versus no therapy in patients with non transfusion-dependent thalassaemia: a multicenter prospective comparison from the MIOT network. Annals of Hematology, 2018, 97, 1925-1932.	1.8	5
77	Prevalence of extramedullary hematopoiesis, renal cysts, splenic and hepatic lesions, and vertebral hemangiomas among thalassemic patients: a retrospective study from the Myocardial Iron OverloadÂin Thalassemia (MIOT) network. Annals of Hematology, 2019, 98, 1333-1339.	1.8	5
78	Prospective CMR Survey in Children With Thalassemia Major. JACC: Cardiovascular Imaging, 2020, 13, 1284-1286.	5.3	5
79	Setting for â€œNormalâ€•Serum Ferritin Levels in Patients with Transfusion-Dependent Thalassemia: Our Current Strategy. Journal of Clinical Medicine, 2021, 10, 5985.	2.4	5
80	Is there a difference in phenotype between males and females with non-transfusion-dependent thalassemia? A cross-sectional evaluation. Hematology, 2018, 23, 522-525.	1.5	4
81	The planimetric Grothoff's criteria by cardiac magnetic resonance can improve the specificity of left ventricular non-compaction diagnosis in thalassemia intermedia. International Journal of Cardiovascular Imaging, 2020, 36, 1105-1112.	1.5	4
82	Relationship between uric acid levels and cardiometabolic findings in a large cohort of Î²-thalassemia major patients. Biomarkers in Medicine, 2018, 12, 341-348.	1.4	3
83	Red blood cell consumption in a large cohort of patients with thalassaemia: a retrospective analysis of main predictors. Annals of Hematology, 2020, 99, 1209-1215.	1.8	3
84	Absence of T1 Hyperintensity in the Brain of High-risk Patients After Multiple Administrations of High-dose Gadobutrol for Cardiac Magnetic Resonance. Clinical Neuroradiology, 2021, 31, 347-355.	1.9	3
85	LIVER PANCREAS HEART TRIANGLE AND HCV IN THALASSEMIA: EXPANDING THE HORIZON THROUGH BIOMARKER NETWORKS. International Journal of Hematology & Therapy, 2017, 3, 1-6.	0.1	3
86	Genotypic groups as risk factors for cardiac magnetic resonance abnormalities and complications in thalassemia major: a large, multicentre study. Blood Transfusion, 2021, 19, 168-176.	0.4	3
87	Frequency, pattern, and associations of renal iron accumulation in sickle/Î²-thalassemia patients. Annals of Hematology, 2022, 101, 1941-1950.	1.8	3
88	A T2* MRI prospective survey on heart iron in thalassemia major patients treated with deferasirox versus deferiprone and desferrioxamine in monotherapy. Journal of Cardiovascular Magnetic Resonance, 2011, 13, .	3.3	2
89	The use of hydroxyurea in the real life of MIOT network: an observational study. Expert Opinion on Drug Safety, 2022, , 1-8.	2.4	2
90	Prospective cardiac magnetic resonance imaging survey in myelodysplastic syndrome patients: insights from an Italian network. Annals of Hematology, 2021, 100, 1139-1147.	1.8	1

#	Article	IF	Citations
91	Direct Cost Analysis About The Three Chelators For The Treatment Of Thalassemia Patients With Chronic Iron Overload: An Italian Perspective From The MIOT Network. Blood, 2013, 122, 5605-5605.	1.4	1
92	Relationship between pancreatic iron overload, glucose metabolism and cardiac complications in sickle cell disease: An Italian multicentre study. European Journal of Haematology, 2022, 109, 289-297.	2.2	1
93	Pressureâ€“volume relationship by pharmacological stress cardiovascular magnetic resonance. International Journal of Cardiovascular Imaging, 2022, 38, 853-861.	1.5	0